In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 281 to 290 of 404

TitleTypeExpected publication date
Pembrolizumab with platinum-based chemotherapy then pembrolizumab maintenance for treating primary advanced or recurrent endometrial cancer ID6381Technology appraisal guidance
Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]Technology appraisal guidanceTBC
Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361]Technology appraisal guidanceTBC
Pemigatinib for treating myeloid or lymphoid neoplasms with a FGFR1 rearrangement [ID6172]Technology appraisal guidanceTBC
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]Technology appraisal guidanceTBC
PillCam COLON 2 for investigation of the colon through direct visualisationDiagnostics guidance
Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]Technology appraisal guidanceTBC
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]Technology appraisal guidanceTBC
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]Technology appraisal guidanceTBC
Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All